financetom
Business
financetom
/
Business
/
Update: Keyera Provides 2025 Capital Guidance, Three-Year Growth Strategy
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Keyera Provides 2025 Capital Guidance, Three-Year Growth Strategy
Dec 10, 2024 8:31 AM

11:07 AM EST, 12/10/2024 (MT Newswires) -- (Adds analyst comment.)

Keyera (KEY.TO) on Tuesday released its 2025 capital guidance and growth strategy for the three years to 2027.

The oil and gas pipeline and processing company's growth capital expenditures are expected to range between $300 million and $330 million. Maintenance capital is projected at $70 million to $90 million. Growth capital in 2026 and 2027 is expected to average between $350 million and $450 million.

The company said it is on track for another record year for adjusted EBITDA. Keyera expects to achieve the upper end of its compound annual growth rate (CAGR) target for adjusted EBITDA, holding the Marketing segment constant, of 6% to 7% over the 2022 to 2025 time frame.

Keyera is adjusting its growth target to a fee-based adjusted EBITDA calculation, which now excludes the Marketing segment. On this new basis, the company has implemented a target for fee-based adjusted EBITDA to reach 7% to 8% CAGR through 2027.

National Bank of Canada maintained its sector-perform rating and $39.00 price target on Keyera's ( KEYUF ) shares following the news.

The bank said its price target was based on a risk-adjusted dividend yield of 5.5% applied to its estimated 2025 dividend of $2.08 per share, an 12.0x multiple of its estimated 2025 Free-EBITDA and its discounted cash flow per share valuation of $38.00.

Keyera shares were last seen up $0.41 to $44.98 on the Toronto Stock Exchange.

Price: 44.90, Change: +0.33, Percent Change: +0.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Apollo Commercial Real Estate Finance Insider Sold Shares Worth $423,992, According to a Recent SEC Filing
Apollo Commercial Real Estate Finance Insider Sold Shares Worth $423,992, According to a Recent SEC Filing
Apr 17, 2024
04:39 PM EDT, 04/17/2024 (MT Newswires) -- Stuart Rothstein, Director, President & CEO, on April 15, 2024, sold 40,000 shares in Apollo Commercial Real Estate Finance ( ARI ) for $423,992. Following the Form 4 filing with the SEC, Rothstein has control over a total of 415,292 shares of the company, with 415,292 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1467760/000146776024000026/xslF345X03/wk-form4_1713385840.xml ...
AnalytixInsight Names New Interim Chief Executive Officer
AnalytixInsight Names New Interim Chief Executive Officer
Apr 17, 2024
04:41 PM EDT, 04/17/2024 (MT Newswires) -- AnalytixInsight ( ATIXF ) after trade Wednesday said it appointed, effective immediately, Scott Urquhart as the company's interim chief executive officer. He replaces former interim chief executive Natalie Hirsch, whose employment with the company has been terminated, effective immediately. Wednesday's statement noted that Urquhart served as the company's Vice President of Corporate Development...
Expensify Insider Bought Shares Worth $466,734, According to a Recent SEC Filing
Expensify Insider Bought Shares Worth $466,734, According to a Recent SEC Filing
Apr 17, 2024
04:39 PM EDT, 04/17/2024 (MT Newswires) -- Steven J. McLaughlin, 10% Owner, on April 15, 2024, executed a purchase for 324,791 shares in Expensify ( EXFY ) for $466,734. Following the Form 4 filing with the SEC, McLaughlin has control over a total of 10,638,096 shares of the company, with 10,638,096 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1476840/000092963824001516/xslF345X03/form4.xml ...
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing
Apr 17, 2024
04:40 PM EDT, 04/17/2024 (MT Newswires) -- Martine A Rothblatt, Director, Chairperson & CEO, on April 15, 2024, sold 7,200 shares in United Therapeutics ( UTHR ) for $1,682,819. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 130 shares of the company, with 130 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1082554/000141588924010977/xslF345X03/form4-04172024_040401.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved